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dermatologists. Results were evaluated in months 0, 3 and 6 of etanercept treatment. 
RESULTS: Average patients’ age was 46.74 years (21–75 years), average time from 
diagnosis was 24.5 years. Occurrence of psoriatic arthritis was 31.7%. 14.6% of 
patients were work disabled and 16.3% reported incapacity to work with average 
duration of 44.3 days in previous 6 months. Previous biologic treatment: 46.6% of 
patients were naive, 16.8% were after previous failure and 36.5% were after success-
fully ﬁ nished treatment with biologics within 6 previous months. Within the observa-
tion in 0, 3 and 6 months BSA index decreased from 27.12 to 18.64 to 11.47% and 
PASI score from 13.69 to 8.09 to 4.97. Utility measured according to EQ-5D increased 
from 0.7674 to 0.8344 and 0.859 and DLQI index decreased from 10.74 to 6.33 and 
4.24 in months 0, 3 and 6. Percentage of patients required inpatient care decreased 
from 25.8 to 5.0 to 0.66%, additionally average length of stay had shortened from 
15.9 to 11 days. CONCLUSIONS: Signiﬁ cant clinical effect was observed within 3 
and 6 months of etanercept treatment. QoL was increased in vast majority of patients. 
Treatment with etanercept decreased other costs associated with psoriasis—inpatient 
care (frequency and length).
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OBJECTIVES: To evaluate the cost/effectiveness of ziconotide for the spinal neuro-
modulation of cancer pain in real clinical practice, from the third payer point of view. 
METHODS: Clinical and resources consumption data related to intrathecal neuro-
modulation for severe complex pain in progressing cancer patients followed by one 
Italian centre were collected. The observation spanned from implantation to exitus or 
drop-out. Change in Numeric Rating Scale Pain Intensity (NRSPI) is the primary 
outcome of the analysis and the base of the evaluation of number of days with con-
trolled pain (at least 30% reduction). Secondary outcome measures are Karnofsky 
index, Pain Management Index, Edmonton Symptom Assessment Scale score and 
Bowel Function Index. Collected consumption data include drugs, visits, port main-
tenance, and pump recharge and amortization. Current Italian prices, real practice 
acquisition and remuneration costs are applied. RESULTS: Between January 2006 and 
August 2009, 19 patients received intrathecal ziconotide (N: 8) or morphine (N: 11). 
Both groups showed a statistically signiﬁ cant reduction in NRSPI score after 1 week 
(Z:−33,9% vs. M:−10,6%), 2 weeks (Z:−47,9% vs. M:−22,1%), and 3 weeks (Z:−
52,1% vs. M:−26,1%) from implantation, with markedly higher reductions in 
ziconotide patients, although the difference was statistically signiﬁ cant only for the 
ﬁ rst time point. Patients receiving ziconotide lived signiﬁ cantly more days with con-
trolled pain (74% vs. 40%; P < 0,05). Secondary endpoints showed similar trends. 
Average weekly cost is about c240 for ziconotide and c120 for morphine; the main 
cost driver is pharmaceutical cost (respectively 82% and 65% of the total). Higher 
ziconotide acquisition costs are partially offset by minor expenses for adjuvant thera-
pies. The incremental cost for one further day with controlled pain resulted of c50. 
CONCLUSIONS: Ziconotide permits effective treatment of extremely difﬁ cult-to-
manage pain, with improvement of the tolerability and a mild increment of cost, as 
compared to intrathecal therapy without ziconotide.
PSY4
BIOLOGICAL AGENTS FOR THE TREATMENT OF NAIL PSORIASIS: A 
SYSTEMATIC REVIEW OF THE LITERATURE
Naci H1, Green J2, Prasad M3, Fleurence R4
1United BioSource Corporation, London, UK; 2United BioSource Corporation, Lexington, 
MA, USA; 3Merck & Co, Kenilworth, NJ, USA; 4United BioSource Corporation, Bethesda, 
MD, USA
OBJECTIVES: To systematically review the efﬁ cacy of biologics for nail psoriasis in 
plaque psoriasis and psoriatic arthritis. METHODS: MEDLINE and EMBASE were 
searched using predeﬁ ned terms: “psoriasis”, “psoriatic arthritis”, “parapsoriasis”, 
“psoriasis vulgaris”, “inﬂ iximab”, “adalimumab”, “alefacept”, “etanercept”, “goli-
mumab”, and “ustekinumab”. Abstracts from ISPOR, AAD, BAD, EADV, WCD, and 
EULAR from 2006 to 2009 were reviewed. Studies reporting both comparative and 
non-comparative ﬁ ndings from at least one biologic of interest were included if they 
reported the nail psoriasis severity index score (NAPSI), resolution, or remission. 
RESULTS: Thirteen studies were included. Golimumab and inﬂ iximab were assessed 
in randomized controlled trials (RCTs). In a RCT of inﬂ iximab, the % reduction 
(indicating improvement) from baseline NAPSI was signiﬁ cantly greater with inﬂ ix-
imab than with placebo at weeks 10 and 24, with the reduction maintained at 50 
weeks. a similar response through 24 weeks was observed in a RCT of golimumab, 
in which reductions from baseline NAPSI increased over time, from 14 to 24 weeks. 
The third comparative study evaluated adalimumab, etanercept, and inﬂ iximab in an 
observational study, favoring inﬂ iximab. The remaining studies reported ﬁ ndings for 
single-arms and examined inﬂ iximab (3 studies), alefacept (3 studies), adalimumab (3 
studies), and etanercept (1 study). At follow-up periods ranging from 12 to 72 weeks, 
these studies reported modest reductions in NAPSI scores for inﬂ iximab, etanercept, 
alefacept, and adalimumab. CONCLUSIONS: Comparative studies demonstrated that 
golimumab and inﬂ iximab appeared to be effective treatment options for nail psoria-
sis. Inﬂ iximab also has evidence supporting long-term efﬁ cacy at 50 weeks. Evidence 
from non-comparative studies supported the ﬁ ndings of the comparative evidence and 
suggested that there may be moderate nail improvement associated with adalimumab, 
alefacept, and etanercept. No quantitative synthesis of the data could be performed, 
mainly due to the paucity of comparative evidence. Further studies are warranted to 
understand the comparative efﬁ cacy of biologic treatments for nail psoriasis.
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OBJECTIVES: CAPS is a spectrum of rare inherited autoinﬂ ammatory syndromes. It 
is an ultra-orphan disease affecting approximately 70 patients in the UK. CAPS 
patients are at increased risk of developing AA amyloidosis (AA) and subsequent 
end-stage renal failure (ESRF). This study aimed to model the impact of a new treat-
ment, canakinumab, on the progression of AA in patients with CAPS. METHODS: 
A Markov model was developed which comprised four health states: CAPS, CAPS 
with AA, CAPS with ESRF and dead. Based on the literature, 25% of CAPS patients 
are thought to develop AA over their lifetime. The risks of ESRF and death in patients 
with AA were obtained from published observational studies and life expectancy in 
CAPS patients with ESRF was based on expert opinion. Excess mortality in CAPS for 
reasons other than AA was estimated from rheumatoid arthritis, another systemic 
inﬂ ammatory disease. Treatment efﬁ cacy for canakinumab was obtained from the 
results of a pivotal clinical trial. The model was run for a typical adult patient and a 
typical paediatric patient and assumed that AA was not present at treatment initiation. 
RESULTS: Assuming a UK CAPS population of 70 patients, if canakinumab was initi-
ated at the age of 4 years, a total of 18 AA and 8 ESRF cases would be avoided, and 
patients would gain 13.7 years of life on average compared to those not treated with 
canakinumab. Assuming treatment initiation at the age of 38 years (estimated mean 
age at diagnosis), a total of 11 AA and 4 ESRF cases would be avoided and patients 
would gain 10.3 years of life on average. CONCLUSIONS: Based on a model estimat-
ing the progression of AA in CAPS, treatment with canakinumab is associated with a 
gain of 10 to 14 life-years due to a reduced incidence of AA and ESRF.
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OBJECTIVES: Icatibant, a speciﬁ c bradykinin-B2 receptor antagonist, is approved for 
symptomatic treatment of acute attacks of HAE in adults with C1-esterase-inhibitor 
deﬁ ciency. Although no treatment-related serious adverse events were reported during 
randomized clinical trials with icatibant in HAE, a study of outcomes in normal clini-
cal practice is important since bradykinin-B2 receptor antagonism is a new therapeutic 
approach. The Icatibant Outcome Survey (IOS) is an international, multicentre, pro-
spective observational study designed to provide further information on the safety and 
effectiveness of icatibant in an unselected patient population. METHODS: The study 
population is all patients receiving icatibant outside of the blinded controlled studies. 
After obtaining approval from local Institutional Review Board or Ethics Committees, 
treating physicians are invited to enrol consenting patients and to participate in the 
study. a series of survey forms are used to record baseline data relating to relevant 
medical history and demographic information at study entry; details of previous HAE 
attacks, icatibant administration and outcomes; hematological, liver function and 
plasma lipid status; and any adverse events. Routine data entry occurs electronically 
via a secure link and participating physicians are encouraged to update records for 
each patient at 6-monthly intervals. Any serious adverse events will be notiﬁ ed imme-
diately in accordance with normal pharmacovigilance practice. Data harvested from 
the database will be summarised and scrutinised by an independent Steering Commit-
tee. RESULTS: Data collection commenced in July 2009 and the ﬁ rst analysis was 
done early 2010. CONCLUSIONS: The Icatibant Outcome Survey will provide 
further prospective data on safety and outcomes of use of this novel drug for acute 
treatment of HAE attacks in a ‘real world’ setting. 
